Oren Livnat expects MannKind’s inhaled insulin’s new label will be a real game-changer.
Mannkind caught a price target boost from Maxim in the wake of a positive label revision for Afrezza.
Investors are racing to buy MannKind Corporation (NASDAQ:MNKD) shares following the news that the FDA has approved a labeling revision for the company’s diabetes …
MannKind Corporation (NASDAQ:MNKD) and One Drop announced the first step of their collaboration with the launch of the A-ONE study, a randomized controlled …
In a research report published on Monday, RBC Capital analyst Adnan Butt reiterated an Outperform rating on shares of MannKind Corporation (NASDAQ:MNKD), but reduced the …
In a research report published Friday, MLV analyst Arlinda Lee reiterated a Hold rating on MannKind Corporation (NASDAQ:MNKD) with a price target of …
J.P.
In a research report released today, Jefferies analyst Shaunak Deepak initiated coverage on shares of MannKind (NASDAQ:MNKD) with a Buy rating and a $10 price target, …
